<ISPH>
Hey Mike - looks like you are about a year late in suggesting we look at it - it's been about a 8-bagger in that time. <g>
I've never followed them, but I'll take a look.
Here's an abstract about their allergy treatment:
February 2003, part 2 ? Volume 111 ? Number 2
16 INS37217 Intranasal, a P2Y2 Receptor Agonist, Is a Novel Treatment for Allergic Rhinitis
A. E. Schaberg1
E. O. Meltzer2
C. F. LaForce3
D. S. Pearlman4
J. C. Ice1
L. M. LaVange1
D. J. Kellerman1
1Inspire Pharmaceuticals, Inc,
Durham, NC
2Allergy and Asthma Medical Group and Research Center,
San Diego, CA
3North Carolina Clinical Research,
Raleigh, NC
4Clinical Research Centers of Colorado,
Denver, CO.
RATIONALE: INS37217, a P2Y2 receptor agonist that regulates mucosal hydration and mucociliary function in respiratory epithelial tissue, is being developed as a treatment for allergic rhinitis.
METHODS: In this 3-center, double-blind, parallel-group, tolerability study, 59 subjects with symptoms of perennial allergic rhinitis (PAR) received one of three concentrations of INS37217 (5 mg/ml, 10 mg/ml, or 40 mg/ml delivered as two 100 µl sprays in each nostril) or placebo spray BID for 6 days and recorded symptoms.
RESULTS: All concentrations of INS37217 were well tolerated and all subjects completed the study. Symptom scores were significantly reduced compared with placebo from the baseline (saline) run-in period for all concentrations of INS37217 on multiple individual symptoms on multiple study days, most notably for the 10 mg/ml concentration. INS37217 10 mg/ml treatment resulted in significantly greater reduction in either AM or PM scores compared with placebo for nasal congestion (Day 5, p=0.001), post-nasal drip (Days 5 and 6, p0.010), rhinorrhea (Day 5, p=0.017), and facial pain and pressure (Days 1, 2, 5, and 6, p0.05). Morning total nasal symptom scores (0-15 scale) over the treatment period were reduced ?0.97 (0.51), ?1.15 (0.53), and ?1.00 (0.52) in the INS37217 5 mg/ml, 10 mg/ml, and 40 mg/ml treatment groups, respectively, compared with ?0.13 (0.52) for placebo (p=0.139, INS37217 vs placebo).
CONCLUSION: Although this study was neither designed nor powered as an efficacy study, patient-recorded symptom scores were statistically significantly reduced with INS37217 treatment compared with placebo for multiple symptoms during the first week of treatment in a small sample of subjects with PAR.
Funding: Inspire Pharmaceuticals
Can't say I've ever heard about the P2Y2 receptor before reading this.
Peter |
